of the bottom of the well of genetic variation in humans. In human genetics, it is generally assumed that when the same variant is found in more than one individual, it arose once in an ancestor shared by those individuals, rather than through independent mutations of the same site. However, at a particular class of site, called CpG dinucleotides, the researchers make a convincing case that variants observed in multiple individuals often reflect mutational recurrence.
In support of their assertion, the researchers find that discovery rates for new CpG dinucleotide mutations decrease in samples larger than 20,000 individuals. This provides further evidence that the size of the ExAC cohort is sufficiently large that we are beginning to saturate this class of human genetic variation, at least within the exome. It is worth noting, however, that CpG dinucleotides have a highly elevated mutation rate in human genomes, making the number of samples needed to observe such saturation much lower than for other kinds of variants. Nonetheless, this exciting finding presages what lies ahead, as larger aggregate analyses of exomes and genomes are performed.
Third, ExAC promotes the discovery of genes involved in rare diseases. In 2009, my group and others showed how exome sequencing could be used to identify Mendelian-disease genes or to diagnose Mendelian disease 1, 7, 8 . Because there are tens of thousands of genetic variants in an exome, these strategies depended on effectively filtering out common variants, which are not likely to cause Mendelian disorders. At that time, databases of common variants were uneven and of suspect quality. Although ESP greatly improved the situation by uniformly and systematically cataloguing both common and rare variants across the exome 4 , ExAC is an order of magnitude larger, and so enables better filtering. This is especially relevant for exome sequencing of non-European, non-African-American individuals, because ExAC provides greater sampling of individuals from outside the United States than ESP does.
On a related point, the study finds that hundreds of variants previously claimed to cause Mendelian disorders occur at implausibly high frequencies. As such, the authors suggest that they be reclassified as benign. A related study 9 shows how ExAC may also force a reassessment of whether some genes are involved at all in particular rare disorders. There is little doubt that ExAC will both refine and accelerate Mendelian-gene discovery and clinical genetics.
Finally, the consortium's approach to data aggregation and sharing is admirable. ExAC is both a technical and political achievement, requiring wrangling not only of data but also of investigators, consents and more from 14 studies -most of which were directed at the genetics of various common diseases.
An ongoing challenge in genomics is balancing the privacy rights of human participants with a strong tradition of promptly and openly sharing data. Building on the precedent of ESP, ExAC hits this balance by publicly releasing aggregate analyses -a catalogue of variants and the frequencies at which they arise -but not data about associated traits or other individual-level information (although raw data for many studies in ExAC is theoretically accessible through restricted databases). In this way, the study maximizes benefit while minimizing harm. These data have already been available on a terrifically intuitive website for nearly two years (http://exac.broadinstitute.org/), and the site has accrued more than 4 million page views.
If there is one take-home message, it is that there is incredible value in aggregating sequencing data across genomic studies. As the exomes aggregated by ExAC represent just a small fraction of the human samples that have been subjected to exome or genome sequencing so far, we can and should do better. In the coming decade, the number of human genomes that will be sequenced in some manner will grow to at least tens of millions and, by the end of this century, perhaps even billions. 
NEUROSCIENCE

Flipping the sleep switch
Inactivation of a group of sleep-promoting neurons through dopamine signalling can cause acute or chronic wakefulness in flies, depending on changes in three different potassium-channel proteins. See Letter p.333
any people have nodded off during a long road trip, or lain in bed desperately trying to fall asleep. These experiences illustrate real-world consequences of an improperly maintained balance between sleep-and wake-promoting neural circuits. On page 333, Pimentel et al. 1 describe the identification of a bona fide molecular switch that allows wake-promoting signals to turn off individual sleep-promoting neurons to regulate waking. These findings open up avenues for understanding the complexity of sleep regulation in healthy individuals and during disease.
Multiple sleep and wake circuits are found throughout the mammalian central nervous system and are believed to interact in a mutually inhibitory manner 2, 3 . A similar organization is found in the fruitfly Drosophila, in which independent sleep and wake centres cooperate to produce stable sleep and wake patterns. Flies are less complex than mammals, and their neuronal circuits can be easily manipulated using genetic tools, making them more tractable as study subjects.
Perhaps the best-characterized sleep centre in flies is composed of neurons that project into a brain region called the dorsal fan-shaped body (dFB) [4] [5] [6] . The wake-promoting neurons (dopaminergic neurons) in the fly's brain release the neurotransmitter molecule dopamine. To better understand the molecular logic used by these two sets of neurons to regulate the sleep-to-wake transition, Pimentel et al. stimulated the wake-promoting neurons to release dopamine while they simultaneously recorded the activity of the sleep-promoting dFB neurons.
The authors genetically engineered the flies' dopaminergic neurons so that their activity could be modulated by a pulse of light -a technique known as optogenetics. Flies were restrained by fixing their heads, such that they could freely move their legs on a treadmill when awake. With this set-up, the physiological activity of the sleep-promoting dFB neurons and their response to the activation of dopaminergic wake-promoting neurons could be studied in real time.
When a fly spontaneously went to sleep for at least five minutes, the researchers optogenetically activated its dopaminergic neurons and measured the effect on the dFB neurons. In the sleeping flies, in the absence of dopamine signalling, the dFB neurons showed spikes of activity, which the researchers term the 'ON' state (Fig. 1a) . Following acute activation of their dopaminergic neurons, the flies rapidly awoke. Pimentel and colleagues found that the dFB neurons were transiently hyperpolarized at this point (that is, the electrical potential across the cells' membranes sharply decreased), which inhibited neuronal firing. This change in membrane potential was brought about by a movement of potassium ions out of the cell through an unidentified potassium-channel protein.
Next, Pimentel et al. applied dopamine directly to dFB dendrites -projections that receive signals from other neurons and transmit them to the body of the dFB neuron. Again, they observed hyperpolarization and suppression of firing, confirming that the effects of optogenetic activation reflected the direct consequences of increased dopamine signalling. The authors mapped this response to the Dop1R2 dopamine receptor protein, which is expressed in dFB neurons. Moreover, pharmacological and genetic studies demonstrated that Dop1R2 activation by dopamine inhibits dFB spiking through the G i/o signalling pathway, which in turn modulates physiological properties of the neuron. Thus, the researchers have found a molecular mechanism by which a wake-promoting dopamine signal directly and acutely inhibits dFB spiking during the ON state, allowing flies to rapidly wake up as environmental conditions demands (Fig. 1b) .
In addition to this acute response, Pimentel and colleagues showed that longer exposures to dopamine turned off sleep-promoting neurons for extended periods of time. In this setting, dopamine hyperpolarized and inhibited spiking of dFB neurons by modulating the activity of two other potassium channels -one called Shaker and one dubbed Sandman by the authors. During prolonged exposure to dopamine, Sandman channels, which are normally retained in intracellular vesicles, are inserted into the membrane to chronically inhibit dFB firing. Following chronic inhibition, dFB neurons became impervious for up to an hour to a variety of stimuli that ordinarily trigger neuronal impulses . This 'OFF' state persisted even in the absence of a steady supply of dopamine, and produced a prolonged period of insomnia (Fig. 1c) . Thus, the arousing effects of dopamine occur through two distinct mechanisms that operate on different timescales.
These results are truly exciting because they describe how circuit interactions are integrated at the level of individual neurons to maintain stable sleep-wake patterns. These types of analysis, particularly as they pertain to sleep, have proved to be inherently difficult in more-complex animals 7 . It will be interesting now to turn to mammals, looking at various types of sleep-promoting neuron to determine nwhether the switching mechanisms identified by Pimentel et al. in flies have similar roles in a more complex setting. In particular, it remains to be seen how this molecular-switching mechanism can be integrated into models that conceptualize sleep regulation as a winnertakes-all competition between opposing sleeppromoting and wake-promoting circuits 2 . Many avenues for further investigation remain. First, it will be interesting to find the switching mechanism that mediates the transition from waking to sleep, which has obvious clinical utility for conditions such as insomnia and Alzheimer's disease. Second, the dFB is made up of diverse populations of neurons that receive information from a large variety of neurotransmitters and neuropeptide molecules 8 -understanding how dopamine signalling interacts with these other neuroactive compounds will be crucial for truly understanding the molecular logic that underlies sleep regulation.
In summary, Pimentel and colleagues' study is valuable not only for the answers that it has given, but also because it provides the tools and logical framework that open up an area of enquiry that will be fruitful for many years to come. In particular, the ability to target a more precise molecular mechanism in discrete sets of neurons may make it easier to develop better drugs to enhance both sleep and waking with fewer adverse side effects. 1 describe how they have attacked two of the most challenging problems in the field of catalysis using methods more common to the study of metalloenzymes. The first problem is how to pick out from an assembly of potential candidates the active site of a hetero geneous catalyst -a solid that can accelerate reactions of chemical species in the gas phase or in solution -and to determine its structure. The second problem is more specific: how to design an efficient process for selectively converting methane, the main component of natural gas, to a more valuable product. The authors' approach combines powerful spectroscopic techniques with computational modelling, and leads to a detailed picture of a catalytic site that is probably responsible for activating methane so that it can react at room temperature.
There is great interest in transforming methane into more useful liquid fuels such as methanol. But methane is notoriously un reactive, and most transformations require conditions, such as high temperatures, that are unfavourable for the selective formation of a desired product. One prominent exception occurs in microorganisms: certain bacteria use methane as a source of carbon and energy by first converting it to methanol, using enzymes known as methane monooxygenases (MMOs).
In 1997, an iron-containing structure that could be generated in certain zeolites was reported 2 to convert methane to methanol, even at room temperature (Fig. 1) . (Zeolites are crystalline materials containing ordered arrays of pores that can house the active sites of catalysts.) One particularly intriguing aspect of this discovery was that soluble versions of MMO are also based on iron, and feature bi metallic ferrous oxide (Fe 2 O 2 ) cores at their active site 3 . By using various spectroscopic techniques, several research groups have proposed 4, 5 that the iron species of the zeolite system contains an analogous bi metallic structure, known as the α-Fe(ii) centre. But such studies are complicated by the non-uniform nature of heterogeneous catalysts; it is difficult to determine whether a particular spectroscopic feature is associated with the actual active site, rather than reflecting an inactive 'spectator' site, or is a blurred-out average of both. From their interpretation of results using a suite of methods, Snyder et al. propose a quite different structure for the α-Fe(ii) centre.
As a first step, the authors observed changes in the optical spectrum of the iron-containing zeolite as the material was cycled through the various stages of the methanol-forming reaction. This allowed them to assign particular peaks to the reactive states of the iron species α-Fe(ii) and α-O, an intermediate species that forms during the reaction. They could then identify the corresponding features in the spectrum obtained using magnetic circular dichroism (MCD), a technique that is highly sensitive to the molecular and electronic structure of transition-metal centres such as iron. By comparing parameters determined by MCD -as well as the parameters' dependence on temperature and magnetic-field strengthwith those of structurally well-characterized model compounds, the authors concluded that the most probable structure for α-Fe(ii) contains a highly unusual, monometallic iron centre that has a 'square-planar' geometry ( Fig. 1) , whereas α-O is a square-pyramidal Fe(iv)=O structure resulting from the attachment of an oxygen ligand to the top of the square-planar species.
Snyder and colleagues' conclusions were further supported by Mössbauer spectroscopy -another technique often used in bioinorganic chemistry for structural characterization of iron centres -along with computational results. As in earlier work 4 , Mössbauer spectroscopy on the iron-containing zeolite gave an overlay of several signals. This was potentially problematic, because it can be hard to find a priori grounds for assigning different Mössbauer signals to particular metal species. Fortunately, Snyder and co-workers were able to correlate the relative intensity of the largest signal quite precisely with the relative concentration of the active species, as determined from the amount of reaction product ultimately obtained. This provides more confidence that the authors have assigned the correct chemical structures to the active centres, and helps to demonstrate the potential of this multi faceted spectroscopic approach for characterizing heterogeneous catalysts.
There is one caveat: the system under study is particularly well suited to the authors' approach, for two reasons. First, the active site constitutes a large fraction of the total iron species in the zeolite, about 80% or more; and ) combines with that oxygen to give a bound form of methanol, which can then be extracted from the zeolite by water. Snyder et al. 1 report that the iron atom in α-Fe(ii) is constrained to an unusual 'square-planar' geometry within a ring of atoms in the zeolite; ring atoms are shown around the iron atom in α-Fe(ii), but are not shown for the other iron-containing structures. Fe, iron; Si, silicon; Al, aluminium.
CATALYSIS
Elusive active site in focus
The identification of the active site of an iron-containing catalyst raises hopes of designing practically useful catalysts for the room-temperature conversion of methane to methanol, a potential fuel for vehicles. See Letter p.317
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